title: Molecular signatures in urologic tumors.
abstract: Urologic tumors continue to represent a huge fraction of cancer cases in the United States, with over 376,310 estimated new diagnoses in 2013. As with many types of tumors, urologic tumors vary greatly in their phenotype, ranging from minimally invasive to malignancies possessing great metastatic potential. The increasing need for more efficient and less invasive methods of cancer detection, as well as the ability to predict severity of the disease phenotype is readily evident--yet reliable methods remain elusive in a clinical setting today. Comprehensive panels of gene clusters are being developed toward the generation of molecular signatures in order to better diagnose urologic malignancies, and identify effective treatment strategies in the emerging era of personalized medicine. In this review, we discuss the current literature on the credibility and biomarker value of such molecular signatures in the context of clinical significance relating to the pathological aggressiveness of urologic tumors (prostate, bladder and renal cancer)--also exploiting their predictive potential in the response to treatment.
authors.affiliation: Departments of Urology, University of Kentucky College of Medicine, Lexington, Kentucky, KY 40536, USA. nkypr2@uky.edu.
authors.forename: Spencer
authors.initials: S
authors.lastname: Larkin
authors.forename: Natasha
authors.initials: N
authors.lastname: Kyprianou
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D006801:Humans; D014571:Urologic Neoplasms / Q000175:diagnosis / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor
references.citation: Oncology (Williston Park). 2012 Mar;26(3):290-301
references.pmid: 22545314
references.citation: Clin Cancer Res. 2009 Jul 15;15(14):4706-11
references.pmid: 19584163
references.citation: Med Sci Monit. 2004 Oct;10(10):RA235-41
references.pmid: 15448614
references.citation: Cancer. 2010 Dec 15;116(24):5637-49
references.pmid: 20737563
references.citation: Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14531-6
references.pmid: 16983094
references.citation: Carcinogenesis. 2013 Mar;34(3):530-8
references.pmid: 23188675
references.citation: PLoS One. 2009 Jul 14;4(7):e6229
references.pmid: 19597549
references.citation: Int J Oncol. 2012 Nov;41(5):1871-8
references.pmid: 22961325
references.citation: Mod Pathol. 2008 Dec;21(12):1451-60
references.pmid: 18500259
references.citation: Biotechniques. 2002 Sep;33(3):632, 634, 636-49
references.pmid: 12238773
references.citation: Nature. 2006 May 25;441(7092):437-43
references.pmid: 16724055
references.citation: Oncologist. 2011;16(3):264-75
references.pmid: 21339259
references.citation: Cancer Res. 1998 Dec 1;58(23):5315-20
references.pmid: 9850056
references.citation: J Hematol Oncol. 2012 Mar 14;5:9
references.pmid: 22417299
references.citation: J Pathol. 2011 Jun;224(2):270-9
references.pmid: 21547910
references.citation: Nat Genet. 2009 May;41(5):619-24
references.pmid: 19396168
references.citation: Cell Mol Biol (Noisy-le-grand). 2012 Sep 10;Suppl.58:OL1744-51
references.pmid: 22992440
references.citation: Clin Chem. 2011 Nov;57(11):1474-5
references.pmid: 21878561
references.citation: Front Endocrinol (Lausanne). 2012 Jul 18;3:85
references.pmid: 22826702
references.citation: Am J Pathol. 2012 Aug;181(2):401-12
references.pmid: 22705054
references.citation: Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1497-509
references.pmid: 22736790
references.citation: Oncol Rep. 2012 Apr;27(4):1193-9
references.pmid: 22200788
references.citation: J Cell Mol Med. 2011 Feb;15(2):187-95
references.pmid: 21155973
references.citation: Cell Signal. 2012 Jun;24(6):1323-32
references.pmid: 22570869
references.citation: Cancer Res. 2009 Aug 1;69(15):6027-32
references.pmid: 19584279
references.citation: Ann Oncol. 2008 Sep;19 Suppl 7:vii91-5
references.pmid: 18790987
references.citation: Libyan J Med. 2009 Dec 01;4(4):143-5
references.pmid: 21483537
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4757-64
references.pmid: 17947723
references.citation: Eur Urol. 2011 May;59(5):671-81
references.pmid: 21296484
references.citation: Adv Urol. 2012;2012:503271
references.pmid: 22761614
references.citation: J Mol Biol. 2008 Feb 22;376(3):827-38
references.pmid: 18177895
references.citation: Mol Cancer. 2012 Feb 10;11:7
references.pmid: 22325146
references.citation: J Clin Oncol. 2006 Feb 10;24(5):727-35
references.pmid: 16418497
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: N Engl J Med. 2004 May 27;350(22):2239-46
references.pmid: 15163773
references.citation: Urol Ann. 2011 Jan;3(1):8-13
references.pmid: 21346826
references.citation: Int J Cancer. 2011 Feb 1;128(3):608-16
references.pmid: 20473869
references.citation: Oncol Rep. 2012 Aug;28(2):409-17
references.pmid: 22641253
references.citation: Hum Pathol. 2011 Apr;42(4):455-81
references.pmid: 21106220
references.citation: Urology. 2005 Apr;65(4):713-8
references.pmid: 15833514
references.citation: Am J Pathol. 1999 Oct;155(4):1129-36
references.pmid: 10514396
references.citation: J Mol Diagn. 2011 Jan;13(1):29-40
references.pmid: 21227392
references.citation: Cancer Cell. 2008 Jun;13(6):519-28
references.pmid: 18538735
references.citation: Nature. 2003 Sep 18;425(6955):307-11
references.pmid: 13679920
references.citation: Nat Rev Cancer. 2005 Jan;5(1):51-63
references.pmid: 15630415
references.citation: FEBS Lett. 2004 Nov 19;577(3):439-45
references.pmid: 15556624
references.citation: Br Med Bull. 2010;94:49-64
references.pmid: 20418405
references.citation: Cancer Sci. 2007 Dec;98(12):1845-52
references.pmid: 17888029
references.citation: Urology. 2006 Sep;68(3):549-53
references.pmid: 16979735
references.citation: Nature. 2011 Feb 10;470(7333):269-73
references.pmid: 21289624
references.citation: Clin Cancer Res. 2002 Feb;8(2):464-70
references.pmid: 11839665
references.citation: Int J Cancer. 2012 Feb 1;130(3):521-31
references.pmid: 21351095
references.citation: J Urol. 2007 Jul;178(1):301-7
references.pmid: 17499794
references.citation: Crit Rev Oncol Hematol. 2006 Jun;58(3):190-207
references.pmid: 16690321
references.citation: Cell Res. 2005 Jan;15(1):28-32
references.pmid: 15686623
references.citation: JAMA. 2006 Jun 7;295(21):2516-24
references.pmid: 16757724
references.citation: J Clin Oncol. 2005 Feb 10;23(5):1028-43
references.pmid: 15534359
references.citation: Clin Cancer Res. 2009 Nov 15;15(22):7012-9
references.pmid: 19903782
references.citation: BJU Int. 2012 Sep;110(5):630-6
references.pmid: 22353238
references.citation: Cancer Res. 2011 Mar 1;71(5):1978-88
references.pmid: 21324924
references.citation: Ann Intern Med. 2012 Jul 17;157(2):120-34
references.pmid: 22801674
references.citation: Crit Rev Biochem Mol Biol. 2000;35(2):71-103
references.pmid: 10821478
references.citation: Science. 2005 Oct 28;310(5748):644-8
references.pmid: 16254181
references.citation: Oncology (Williston Park). 2011 Sep;25(10):951-8, 960
references.pmid: 22010395
references.citation: Eur Urol. 2011 Nov;60(5):897-904
references.pmid: 21802835
references.citation: Cancer Res. 2000 Dec 15;60(24):7075-83
references.pmid: 11156414
references.citation: Cancer Cell. 2013 Jan 14;23(1):35-47
references.pmid: 23260764
references.citation: J Urol. 2003 Nov;170(5):1872-6
references.pmid: 14532796